Nara Organics Formula Recall Follows Three Confirmed Infant Botulism Cases

The voluntary recall covers every 400 g and 700 g can distributed to Target stores and online between July 2025 and June 2026. Product codes beginning 408, 708, 709 and specific lot strings such as 125075E14F2 are affected. Powdered formula can harbor Clostridium botulinum spores that germinate in the immature gut, producing neurotoxin that causes descending flaccid paralysis. Unlike the 2022 Abbott recall driven by Cronobacter, this outbreak involves a low-market-share organic brand yet carries equivalent urgency because no heat treatment eliminates spores once introduced during manufacturing.

Context from prior CDC surveillance shows powdered infant formula has been implicated in roughly 15 percent of U.S. infant botulism cases since 2010, often without identifiable contamination events until clinical clusters appear. The current investigation includes culture of household-retained cans and whole-genome sequencing of clinical isolates to confirm clonal identity. Because Nara accounts for under 1 percent of sales, the absolute number of exposed infants is small, yet any single case can produce irreversible respiratory failure if antitoxin administration is delayed.

Next steps include expanded lot testing by FDA laboratories, possible seizure authority if voluntary compliance falters, and enhanced retail notification. Clinicians should report any floppy-infant presentations with formula history to state health departments for expedited antitoxin release from the CDC stockpile. Long-term questions center on whether current powdered-formula manufacturing standards sufficiently control spore ingress at the dry-blending stage.